We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Higher values of R2* (the magnetic resonance transverse relaxation rate) found in the substantia nigra (SN) likely reflect greater iron content and are associated with worse long-term outcomes after stroke, according to a study published online March 12 i
Shield Therapeutics has revealed that the US Food and Drug Administration will make a decision on its application to market Feraccru in the US by July 27 next year.